Motley Fool
BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide
📊
AI Sentiment
Positive
6/10
- Home
- ROIV
as of 03-06-2026 3:39pm EST
$28.58
$1.14
-3.84%
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 20.7B | IPO Year: | 2021 |
| Target Price: | $27.56 | AVG Volume (30 days): | 6.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.88 | EPS Growth: | -104.59 |
| 52 Week Low/High: | $8.73 - $30.03 | Next Earning Date: | N/A |
| Revenue: | $29,053,000 | Revenue Growth: | -76.72% |
| Revenue Growth (this year): | -65.06% | Revenue Growth (next year): | 385.85% |
| P/E Ratio: | -33.76 | Index: | N/A |
| Free Cash Flow: | -844050000.0 | FCF Growth: | N/A |
AI-Powered ROIV Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 73.17%
73.17%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Roivant Sciences Ltd. (ROIV)
Torti Frank
Sell
President and Vant Chair
ROIV Feb 23, 2026
Avg Cost/Share
$27.51
Shares
587,390
Total Value
$16,159,098.90
Owned After
13,736,547
SEC Form 4
Torti Frank
Sell
President and Vant Chair
ROIV Feb 20, 2026
Avg Cost/Share
$27.15
Shares
1,012,610
Total Value
$27,492,361.50
Owned After
13,736,547
SEC Form 4
Torti Frank
Sell
President and Vant Chair
ROIV Feb 19, 2026
Avg Cost/Share
$27.42
Shares
1,400,000
Total Value
$38,388,000.00
Owned After
13,736,547
SEC Form 4
Venker Eric
Sell
President & Immunovant CEO
ROIV Feb 13, 2026
Avg Cost/Share
$26.49
Shares
200,000
Total Value
$5,298,000.00
Owned After
1,654,597
SEC Form 4
Sukhatme Mayukh
Sell
President & CIO
ROIV Feb 9, 2026
Avg Cost/Share
$26.47
Shares
339,441
Total Value
$8,985,003.27
Owned After
19,148,664
SEC Form 4
Venker Eric
Sell
President & Immunovant CEO
ROIV Jan 12, 2026
Avg Cost/Share
$21.92
Shares
200,000
Total Value
$4,384,000.00
Owned After
1,654,597
SEC Form 4
Venker Eric
Sell
President & Immunovant CEO
ROIV Dec 24, 2025
Avg Cost/Share
$22.53
Shares
75,000
Total Value
$1,689,750.00
Owned After
1,654,597
SEC Form 4
Pulik Richard
Sell
CFO
ROIV Dec 23, 2025
Avg Cost/Share
$22.42
Shares
406,731
Total Value
$9,122,307.09
Owned After
239,413
Venker Eric
Sell
President & Immunovant CEO
ROIV Dec 23, 2025
Avg Cost/Share
$22.45
Shares
200,000
Total Value
$4,490,000.00
Owned After
1,654,597
SEC Form 4
Gold Daniel Allen
Sell
Director
ROIV Dec 17, 2025
Avg Cost/Share
$23.08
Shares
777,332
Total Value
$17,935,594.88
Owned After
16,697,727
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Torti Frank | ROIV | President and Vant Chair | Feb 23, 2026 | Sell | $27.51 | 587,390 | $16,159,098.90 | 13,736,547 | |
| Torti Frank | ROIV | President and Vant Chair | Feb 20, 2026 | Sell | $27.15 | 1,012,610 | $27,492,361.50 | 13,736,547 | |
| Torti Frank | ROIV | President and Vant Chair | Feb 19, 2026 | Sell | $27.42 | 1,400,000 | $38,388,000.00 | 13,736,547 | |
| Venker Eric | ROIV | President & Immunovant CEO | Feb 13, 2026 | Sell | $26.49 | 200,000 | $5,298,000.00 | 1,654,597 | |
| Sukhatme Mayukh | ROIV | President & CIO | Feb 9, 2026 | Sell | $26.47 | 339,441 | $8,985,003.27 | 19,148,664 | |
| Venker Eric | ROIV | President & Immunovant CEO | Jan 12, 2026 | Sell | $21.92 | 200,000 | $4,384,000.00 | 1,654,597 | |
| Venker Eric | ROIV | President & Immunovant CEO | Dec 24, 2025 | Sell | $22.53 | 75,000 | $1,689,750.00 | 1,654,597 | |
| Pulik Richard | ROIV | CFO | Dec 23, 2025 | Sell | $22.42 | 406,731 | $9,122,307.09 | 239,413 | |
| Venker Eric | ROIV | President & Immunovant CEO | Dec 23, 2025 | Sell | $22.45 | 200,000 | $4,490,000.00 | 1,654,597 | |
| Gold Daniel Allen | ROIV | Director | Dec 17, 2025 | Sell | $23.08 | 777,332 | $17,935,594.88 | 16,697,727 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 6, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 6, 2026 · 100% conf.
AI Prediction SELL
1D
+0.45%
$25.94
Act: +8.06%
5D
-5.41%
$24.42
Act: +2.44%
20D
+2.27%
$26.41
Price: $25.82 Prob +5D: 0% AUC: 1.000
0001635088-26-000009
roiv-20260206false000163508800016350882026-02-062026-02-060001635088roiv:WhollyOwnedSubsidiariesAddressNYMember2026-02-062026-02-060001635088roiv:WhollyOwnedSubsidiariesAddressSwitzerlandMember2026-02-062026-02-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 6, 2026 Roivant Sciences Ltd. (Exact Name of Registrant as Specified in Charter)
Bermuda001-4078298-1173944 (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
7th Floor 50 Broadway London SW1H 0DB United Kingdom
1 Pennsylvania Plaza Floor 54 New York, NY 101191
Viaduktstrasse 8 4051 Basel Switzerland1 (Addresses of Principal Executive Offices, and Zip Code) +44 207 400 3347 Registrant’s Telephone Number, Including Area Code Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
oWritten communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Shares, $0.0000000341740141 per shareROIVThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
1 Addresses of wholly-owned subsidiaries of the Registrant.
Item 2.02. Results of Operations and Financial Condition. On February 6, 2026, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth under this “Item 2.02. Results of Operations and Financial Condition” (including Exhibit 99.1) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, other than to the extent that such filing incorporates by reference any or all of such information by express reference thereto.
Item 9.01. Financial Statements and Exhibits. (d)Exhibits.
Exhibit No.Description of Exhibit 99.1Roivant Science Ltd. Press Release, dated February 6, 2026 104Cover Page Interactive Data File (embedded with Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ROIVANT SCIENCES LTD.
By: /s/ Keyur Parekh Name: Keyur Parekh Title: Authorized Signatory
Dated: February 6, 2026
2025 Q3 Q3 2025 Earnings
8-K Nov 10, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 10, 2025
0001140361-25-041269
false000163508800016350882025-11-102025-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 10, 2025
Roivant Sciences Ltd.
(Exact name of registrant as specified in its charter)
Bermuda
001-40782
98-1173944
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
7th Floor
50 Broadway
London SW1H 0DB
United Kingdom
(Address of principal executive offices, and Zip Code)
+44 207 400-3347
Registrant’s Telephone Number, Including Area Code
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Shares, $0.0000000341740141 per share
ROIV
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.
Results of Operations and Financial Condition.
On November 10, 2025, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information set forth under this “Item 2.02. Results of Operations and Financial Condition” (including the exhibit thereto) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, other than to the extent that such filing incorporates by reference any or all of such information by express reference thereto.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description of Exhibit
99.1
Roivant Sciences Ltd. Press Release, dated November 10, 2025.
104
Cover Page Interactive Data File (embedded with Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ROIVANT SCIENCES LTD.
By:
/s/ Keyur Parekh
Name: Keyur Parekh
Title: Authorized Signatory
Dated: November 10, 2025
2025 Q2 Q2 2025 Earnings
8-K Aug 11, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 11, 2025
0001140361-25-029998
false000163508800016350882025-08-112025-08-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 11, 2025
Roivant Sciences Ltd.
(Exact Name of Registrant as Specified in Charter)
Bermuda
001-40782
98-1173944
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
7th Floor
50 Broadway
London SW1H 0DB
United Kingdom
(Address of Principal Executive Offices, and Zip Code)
+44 207 400-3347
Registrant’s Telephone Number, Including Area Code
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Shares, $0.0000000341740141 per share
ROIV
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.
Results of Operations and Financial Condition.
On August 11, 2025, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information set forth under this “Item 2.02. Results of Operations and Financial Condition” (including the exhibit thereto) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, other than to the extent that such filing incorporates by reference any or all of such information by express reference thereto.
Item 9.01.
Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit No.
Description of Exhibit
99.1
Roivant Science Ltd. Press Release, dated August 11, 2025
104
Cover Page Interactive Data File (embedded with Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ROIVANT SCIENCES LTD.
By:
/s/ Keyur Parekh
Name: Keyur Parekh
Title: Authorized Signatory
Dated: August 11, 2025
Latest Roivant Sciences Ltd. News
ROIV Breaking Stock News: Dive into ROIV Ticker-Specific Updates for Smart Investing
Investor's Business Daily
Moderna Stock Pops After Inking $950 Million Covid Vaccine Settlement
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
A Look At Roivant Sciences (ROIV) Valuation After Recent Share Price Strength
📈
AI Sentiment
Highly Positive
8/10
Barrons.com
Moderna Settles a Covid Vaccine Patent Lawsuit. What It Means for the Stock.
📈
AI Sentiment
Highly Positive
8/10
Zacks
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS
📊
AI Sentiment
Positive
7/10
The Wall Street Journal
Stocks to Watch Wednesday: Coinbase, CrowdStrike, Gitlab, Moderna
📉
AI Sentiment
Negative
2/10
Investor's Business Daily
Moderna Pops After Inking $950 Million Covid Vaccine Settlement
24/7 Wall St.
Moderna and Ross Stores Lead Stock Gainers on Wednesday
📈
AI Sentiment
Highly Positive
9/10
Compare ROIV vs Leading Stocks
See how ROIV stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ROIV Roivant Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.